Participants
obesity, fasting blood glucose, pancreatic injury, arrhythmia, blood loss, malignancy, Cushing’s syndrome, depression, drug abuse, trauma, ideation, mental illness, thyroid C-cell carcinoma, infection, angina pectoris, weight loss, hypoglycaemia, retinopathy, sinus arrhythmia, ischemic stroke, pre-excitation syndrome, overweight, allergies
OBESITY, ARRHYTHMIA, BLOOD LOSS, HEART, CHRONIC HEART FAILURE, HAEMOGLOBINOPATHY, CHRONIC PANCREATITIS, THIRD DEGREE ATRIOVENTRICULAR BLOCK, TYPE 2 DIABETES, ASYMPTOMATIC HYPOGLYCAEMIA, RIGHT BRANCH BUNDLE BLOCK, INFECTION, HYPOGLYCAEMIA, RETINOPATHY, UNCONTROLLED HYPERTENSION, MYOCARDIAL INFARCTION, MULTIPLE ENDOCRINE NEOPLASIA, TRANSIENT ISCHEMIC ATTACK, LONG QT SYNDROME, CARDIOMYOPATHY, HAEMOLYTIC ANAEMIA, ISCHEMIC STROKE, PRE-EXCITATION SYNDROME, SICKLE CELL ANAEMIA, ALLERGIES, GALLBLADDER DISEASE
Participants were eligible for the study if they were adults (aged 18–75 years, both inclusive), overweight (BMI ≥ 24 kg/mParticipants were excluded if they had known allergies to the study drug or any components of the formulation or drugs of the same class; had self-reported body weight fluctuated by more than 5% in the 12 weeks before screening with diet and exercise alone; had used GLP-1 receptor agonists and co-agonists, anti-obesity drugs, glucose-lowering drugs, Chinese herbal medicine or health products that affect body weight, or investigational medication in other clinical trials within 3 months before screening; had a HbA1c level of 6.5% or above at screening or history of type 1 or type 2 diabetes; had a screening fasting blood glucose level of 7.0 mmol/L or above or 11.1 mmol/L or above 2 hours after a 75 g oral glucose tolerance test; had severe hypoglycaemia or recurrent symptomatic hypoglycaemia two times or more within 6 months; had obesity caused by increased cortisol hormone (such as Cushing’s syndrome), pituitary gland or hypothalamus injury, or dose reduction or withdrawal of weight loss drugs; had a history of bariatric surgery or planned bariatric surgery or acupuncture for weight loss, liposuction and abdominal fat removal during the study; had a history of moderate to severe depression or severe mental illness; had previous suicidal ideation or suicidal behaviour; had PHQ-9 of 15 points or more at screening; Had answered “yes” to either Question 4 or Question 5 on the “Suicidal Ideation” portion of the C-SSRS at screening; had major and medium-sized surgery, severe trauma or severe infection within 1 month before screening and were determined by the investigator as not being suitable for this study; had blood donation and/or blood loss ≥400 mL or bone marrow donation within 3 months before screening, or haemoglobinopathy, haemolytic anaemia, sickle cell anaemia.Medical history and concomitant disease-related exclusion criteria included retinopathy; uncontrolled hypertension within 1 month before screening; malignancy; myocardial infarction, angina pectoris, acute and chronic heart failure, cardiomyopathy, or cardiac surgery; haemorrhagic or ischemic stroke or transient ischemic attack within 6 months before screening; thyroid C-cell carcinoma, multiple endocrine neoplasia 2A or 2B, or relevant family history; acute or chronic pancreatitis, gallbladder disease, and pancreatic injury; Heart rate <50 beats/min or >100 beats/min on 12-lead ECG at screening; clinically significant cardiac condition at screening including second or third degree atrioventricular block, long QT syndrome, or QTcF >500 ms, left or right bundle branch block, pre-excitation syndrome or other significant arrhythmia (except sinus arrhythmia); average weekly alcohol intake of more than 21 units for males or 14 units for females; and history of drug abuse.Physical examination and laboratory results-related exclusion criteria included serum calcitonin ≥20 ng/L; ALT or AST > 3 × the ULN; serum total bilirubin (TBil) level >1.5 × the ULN; estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m